Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP9 | P14780 | 4/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP12 | P39900 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29300200 | 0.88 | MMP2 (0.53) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL24217604 | 0.86 | KMT2A (0.42) | FOLH1ALDH1A1LMNAPKMALB | |
| SCHEMBL15160764 | 0.83 | KMT2A (0.49) | FOLH1ALDH1A1ALBHPGDNOD1 | |
| SCHEMBL15160683 | 0.83 | KMT2A (0.49) | FOLH1ALDH1A1ALBHPGDNOD1 | |
| SCHEMBL21899464 | 0.82 | ALDH1A1 (0.42) | FOLH1ALDH1A1LMNAPKMALB | |
| SCHEMBL19239689 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAPKMHPGDCASP2 | |
| SCHEMBL15160777 | 0.82 | BLM (0.44) | FOLH1ALDH1A1LMNA | |
| SCHEMBL12919637 | 0.81 | MEN1 (0.55) | FOLH1ALBNOD1 | |
| SCHEMBL24796610 | 0.81 | NOD1 (0.58) | GLP1RNOD1CASP2 | |
| SCHEMBL14952664 | 0.81 | ALDH1A1 (0.41) | FOLH1ALDH1A1LMNAPKMALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FOLH1 335/4885ALDH1A1 3906/4885MMP2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.